NCT06119061View on ClinicalTrials.gov

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With Subarachnoid Hemorrhage

PHASE4RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
DRUG

Telavancin Injection

Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).

Trial Locations (1)

40536

RECRUITING

University of Kentucky, Lexington

Sponsors
All Listed Sponsors
collaborator

Cumberland Pharmaceuticals

INDUSTRY

lead

Aaron Cook

OTHER